Impact of interleukin‐6 on T cells in kidney transplant recipients. (1st December 2022)

• Record Type: Journal Article
• Authors: Chandran, Sindhu; Tang, Qizhi
• Other Names: Knechtle Stuart guestEditor.
• Is Part Of: American journal of transplantation. Volume 22(2022)Supplement 4
• Page Start: 18
• Page End: 27
• Publication Date: 2022-12-01
• Subjects: clinical research/practice -- cytokines/cytokine receptors -- immunobiology -- immunosuppression/immune modulation -- immunosuppressant—fusion proteins and monoclonal antibodies: T cell specific -- kidney transplantation/nephrology -- lymphocyte biology: differentiation/maturation -- rejection: T cell mediated (TCMR) -- tolerance: clinical -- translational research/science; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ajt.17209
• Languages: English
• ISSNs: 1600-6135

Abstract

Abstract : Interleukin‐6 (IL‐6), a multifunctional proinflammatory cytokine, plays a key role in T cell activation, survival, and differentiation. Acting as a switch that induces the differentiation of naïve T cells into Th17 cells and inhibits their development into regulatory T cells, IL‐6 promotes rejection and abrogates tolerance. Therapies that target IL‐6 signaling include antibodies to IL‐6 and the IL‐6 receptor and inhibitors of janus kinases; several of these therapeutics have demonstrated robust clinical efficacy in autoimmune and inflammatory diseases. Clinical trials of IL‐6 inhibition in kidney transplantation have focused primarily on its effects on B cells, plasma cells, and HLA antibodies. In this review, we summarize the impact of IL‐6 on T cells in experimental models of transplant and describe the effects of IL‐6 inhibition on the T cell compartment in kidney transplant recipients.